Baidu
map

Sci Rep:L型氨基酸转运子1的表达可作为膀胱癌预后和治疗指标

2020-02-07 AlexYang MedSci原创

L型氨基酸转运自己1(LAT1)在转运必需氨基酸(包括亮氨酸)中具有作用,其中亮氨酸能够调控mTOR信号途径。最近,有研究人员探索了LAT1在膀胱癌中的表达情况和功能情况,并探究了一种LAT1特异性抑制剂JPH203在膀胱癌中的药理学活性情况。研究发现,LAT1在膀胱癌中的表达要比正常细胞更高。SiLAT1和JHP203能够抑制膀胱癌细胞的细胞增殖和迁移以及侵入能力。HPH203能够抑制90%的亮

L型氨基酸转运自己1(LAT1)在转运必需氨基酸(包括亮氨酸)中具有作用,其中亮氨酸能够调控mTOR信号途径。

最近,有研究人员探索了LAT1在膀胱癌中的表达情况和功能情况,并探究了一种LAT1特异性抑制剂JPH203在膀胱癌中的药理学活性情况。研究发现,LAT1在膀胱癌中的表达要比正常细胞更高。SiLAT1和JHP203能够抑制膀胱癌细胞的细胞增殖和迁移以及侵入能力。HPH203能够抑制90%的亮氨酸摄入。RNA-seq分析鉴定了类胰岛素生长因子结合蛋白5(IGFBP-5)是JPH203的一个下游靶标。JPH203还能够抑制MAPK/Erk、AKT、p70S6K和4EBP-1的磷酸化活性。多变量分析阐释了LAT1的高表达是总生存的一个独立预后因子(HR3.46,P=0.0204)。具有高LAT1和IGFBP-5表达的患者具有低表达患者显著更短的总生存(p=0.0005)。另外,高LAT1的表达与高等级、病理T阶段、LDH和NLR相关。

最后,研究人员指出,LAT1能够明显的导致膀胱癌的恶化。使用JPH203靶向LAT1可能是膀胱癌治疗的一种新的治疗选择。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1756575, encodeId=8e0c1e5657530, content=<a href='/topic/show?id=593e934e22d' target=_blank style='color:#2F92EE;'>#转运子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93472, encryptionId=593e934e22d, topicName=转运子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef3c37178635, createdName=Tamikia, createdTime=Fri Feb 28 01:07:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860868, encodeId=f68e18608685a, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 23 23:07:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696351, encodeId=437c169635116, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Thu Nov 05 14:07:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039967, encodeId=610c103996ee2, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Feb 07 17:07:00 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
    2020-02-28 Tamikia
  2. [GetPortalCommentsPageByObjectIdResponse(id=1756575, encodeId=8e0c1e5657530, content=<a href='/topic/show?id=593e934e22d' target=_blank style='color:#2F92EE;'>#转运子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93472, encryptionId=593e934e22d, topicName=转运子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef3c37178635, createdName=Tamikia, createdTime=Fri Feb 28 01:07:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860868, encodeId=f68e18608685a, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 23 23:07:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696351, encodeId=437c169635116, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Thu Nov 05 14:07:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039967, encodeId=610c103996ee2, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Feb 07 17:07:00 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1756575, encodeId=8e0c1e5657530, content=<a href='/topic/show?id=593e934e22d' target=_blank style='color:#2F92EE;'>#转运子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93472, encryptionId=593e934e22d, topicName=转运子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef3c37178635, createdName=Tamikia, createdTime=Fri Feb 28 01:07:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860868, encodeId=f68e18608685a, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 23 23:07:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696351, encodeId=437c169635116, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Thu Nov 05 14:07:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039967, encodeId=610c103996ee2, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Feb 07 17:07:00 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
    2020-11-05 yzh409
  4. [GetPortalCommentsPageByObjectIdResponse(id=1756575, encodeId=8e0c1e5657530, content=<a href='/topic/show?id=593e934e22d' target=_blank style='color:#2F92EE;'>#转运子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93472, encryptionId=593e934e22d, topicName=转运子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef3c37178635, createdName=Tamikia, createdTime=Fri Feb 28 01:07:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860868, encodeId=f68e18608685a, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 23 23:07:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696351, encodeId=437c169635116, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Thu Nov 05 14:07:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039967, encodeId=610c103996ee2, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Feb 07 17:07:00 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
    2020-02-07 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

相关资讯

Cell Death & Disease:循环RNA FAM114A2能够抑制膀胱癌的进展

大量的证据表明了循环RNAs(circRNAs)在调控癌症发病机理方面起着关键的作用。然而,circRNAs在膀胱泌尿肿瘤(UCB)中的机制仍旧有很多不清楚。最近,有研究人员发现circFAM114A2在UCB组织样本和细胞系中均显著下调,并且表达水平与病理TNM阶段和等级显著相关。功能上讲,circFAM114A2的过表达能够显著的抑制体外UCB细胞的迁移、浸润和增殖,并抑制体内肿瘤的生长。同样

Sci Rep:GSK-3beta的小分子抑制剂9-ING-41能够增强膀胱癌治疗效果

糖原合成酶激酶-3β(GSK-3β)是一个丝氨酸/苏氨酸激酶,被鉴定作为人类膀胱癌的一种潜在的治疗靶标,最近,有研究人员在临床研究中调查了小分子抑制剂9-ING-41在晚期前列腺癌患者中的抗肿瘤效果。研究发现,使用小分子抑制剂9-ING-41治疗能够导致膀胱癌细胞的细胞周期阻滞,细胞自噬和细胞凋亡。在药物组合治疗效果研究中,自噬抑制剂氯喹能够增强小分子抑制剂9-ING-41的抗肿瘤效果。他们的研究

强生竞标收购TARIS公司,以获得其膀胱癌新型靶向递药技术

强生公司(Johnson&Johnson)已竞标美国生物技术公司TARIS Biomedical,以追求在膀胱癌中占有更大的市场份额,但未公开报价。

Eur Urol:肌层浸润膀胱癌患者放疗和化疗后生活质量结果研究

BC2001是最大的肌层浸润膀胱癌膀胱保留治疗随机试验,阐释了添加5-氟尿嘧啶和丝裂霉素C到放疗后对局部控制和膀胱癌特异性生存的改善效果。最近,有研究人员确定了治疗对BC2001参与者健康相关生活质量(HRQoL)的影响情况。研究中,患者在基线时间点、治疗结束后(EoT)和放疗后6、12、24、36、48和60个月时完成膀胱癌症治疗功能评估(FACT-BL)调查问卷。主要终点结果是膀胱癌分量表(B

Sci Rep:尿路上皮性膀胱癌的成纤维细胞确定了与临床结果相关的基质表型

在尿路上皮性膀胱癌(UBC)中,肿瘤与基质细胞的互作关注很少。虽然最近的研究指向了不同的成纤维细胞亚群,但是联系到UBC患者生存的成纤维细胞标记的综合性分析仍旧还没有研究。最近,有研究人员通过对5个选择的成纤维细胞标记的免疫组化分析,调查了它们与344名UBC患者的生存和组织病理特性的相关性情况,其中包括了肌肉浸润案例和非肌肉浸润案例。数据表明组合基质标记在鉴定预后患者亚群中要比单个标记分析更加合

NCCN临床实践指南:膀胱癌(2020.V2)

2020年1月,美国国家综合癌症网络(NCCN)发布了膀胱癌指南2020年第2版,指南主要内容包括: 指南更新摘要 膀胱癌 临床表现和初始评估 非侵袭性或Tis,初步评估/手术治疗 肌层侵袭或转移,初步评估/手术治疗,额外检查 膀胱/移行细胞癌影像学检查 手术治疗原则 病理检查原则 非肌层浸润性膀胱癌复发概率 膀胱癌:非肌层以及移行细胞变异组织学 术后随访 膀胱灌注治疗原则 化疗原则 侵袭性疾病放

Baidu
map
Baidu
map
Baidu
map